Investors

OvaScience is a global fertility company dedicated to improving treatment options for women around the world.

OVAS (Common Stock)
Price & Exchange
$1.43
NASDAQ
Change (%)
 Stock is Up 0.02 (1.42%)
Volume
6,862
08/22/17      10:15 a.m. ET

Minimum 20 minute delay
Refresh quote

Investor Overview

Recent News

More »
DateTitle 
08/03/17OvaScience Reports Second Quarter 2017 Financial Results
– Fertilization of Bovine EggPC Cell-Derived Egg in OvaTure Program on Track for Year-End – – Completed Target Enrollment in OvaPrime Clinical Safety Study; Expect to Announce Initial Safety Data in First 20 Patients by Year-End – – Sufficiently Funded to Support Operations into 1Q 2020, Enabling Key Milestones – – Conference Call Today at 4:30 p.m. ET – WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 3, 2017-- OvaScienceS... 
Printer Friendly Version
07/27/17OvaScience to Host Second Quarter 2017 Financial Results Conference Call
WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 27, 2017-- OvaScienceSM (NASDAQ: OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. ET on Thursday, August 3, 2017 to discuss second quarter 2017 financial results and provide a general corporate update. The conference call may be accessed by dialing +1-888-424-8151 for U.S. ca... 
Printer Friendly Version
06/21/17OvaScience Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 21, 2017-- OvaScience℠, Inc. (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement award to its newly appointed Chief Executive Officer Elect, Christopher Kroeger. The award was approved by OvaScience’s Compensation Committee on June 21, 2017 as an inducement material to him entering into employment w... 
Printer Friendly Version
06/21/17OvaScience Appoints Christopher Kroeger, M.D., M.B.A., as Chief Executive Officer
– Dr. Kroeger's Combined Business and Medical Experience Ideally Suited to Drive Company’s OvaTure and OvaPrime-Focused Strategy – – Company Restructures Organization to Align with R&D Efforts and Extend Cash Runway into Q1 2020, Enabling Key 2019 Milestones – WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 21, 2017-- OvaScience℠, Inc. (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new trea... 
Printer Friendly Version

Upcoming Events

More »
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources